Basic Information
| RNALocate ID: | RLID:11000911 |
| RNA Symbol: | hsa-miR-30a-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-30a |
| RNA ID: | miRBase:MIMAT0000087 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23539611 |
| Tissue/Cell Line: | Seminal plasma |
| Method: | Microarray |
| Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001378 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001379 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001380 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001381 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001382 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001383 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11000903 | Exosome | Primary dendritic cells | 21505438 |
| RLID:11000904 | Exosome | Renal cancer cells | 21670082 |
| RLID:11000905 | Exosome | Brain tissue | 23382797 |
| RLID:11000906 | Exosome | Plasma | 23663360 |
| RLID:11000907 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000908 | Exosome | Cerebrospinal fluid | 25420022 |
| RLID:11000909 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11000910 | Microvesicle | Plasma | 23077538 |
| RLID:11000912 | Microvesicle | Follicular fluid | 23666971 |
| RLID:11000913 | Microvesicle | Hepatoma cells | 23771658 |
| RLID:21000215 | Cytoplasmic stress granule | HeLa cells | 28488892 |
| RLID-D:11000023 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Endothelial cells|Epithelial cells|Kidney tissue|Mast cells|Seminal fluid|Tongue tissue | |
| RLID-D:11000286 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-30a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-36677 |
| MNDR | hsa-miR-30a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-36678 |
| MNDR | hsa-miR-30a-5p | Colorectal adenoma | MNDR-E-MI-36679 |
| MNDR | hsa-miR-30a-5p | Oral squamous cell carcinoma | MNDR-E-MI-36680 |
| MNDR | hsa-miR-30a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-36681 |
| MNDR | hsa-miR-30a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-36682 |
| MNDR | hsa-miR-30a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-36683 |
| MNDR | hsa-miR-30a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-36684 |
| MNDR | hsa-miR-30a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-36685 |
| MNDR | hsa-miR-30a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-36686 |
| MNDR | hsa-miR-30a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-36687 |
| MNDR | hsa-miR-30a-5p | Triple negative breast cancer | MNDR-E-MI-36688 |
| MNDR | hsa-miR-30a-5p | Lupus nephritis | MNDR-E-MI-36689 |
| MNDR | hsa-miR-30a-5p | Thyroid carcinoma anaplastic | MNDR-E-MI-36690 |
| MNDR | hsa-miR-30a-5p | Dermatomyositis | MNDR-E-MI-36691 |
| MNDR | hsa-miR-30a-5p | Prostate cancer | MNDR-E-MI-36692 |
| MNDR | hsa-miR-30a-5p | Gastric cancer | MNDR-E-MI-36693 |
| MNDR | hsa-miR-30a-5p | Gastric lymphoma | MNDR-E-MI-36694 |
| MNDR | hsa-miR-30a-5p | Alzheimer disease | MNDR-E-MI-36695 |
| MNDR | hsa-miR-30a-5p | Bladder cancer | MNDR-E-MI-36696 |
| MNDR | hsa-miR-30a-5p | Esophageal carcinoma | MNDR-E-MI-36697 |
| MNDR | hsa-miR-30a-5p | Sarcoma | MNDR-E-MI-36698 |
| MNDR | hsa-miR-30a-5p | Duchenne muscular dystrophy | MNDR-E-MI-36699 |
| MNDR | hsa-miR-30a-5p | Seizures | MNDR-E-MI-36700 |
| MNDR | hsa-miR-30a-5p | Head and neck cancer | MNDR-E-MI-36701 |
| MNDR | hsa-miR-30a-5p | Leukemia | MNDR-E-MI-36702 |
| MNDR | hsa-miR-30a-5p | Huntington disease | MNDR-E-MI-36703 |
| MNDR | hsa-miR-30a-5p | Chorea | MNDR-E-MI-36704 |
| MNDR | hsa-miR-30a-5p | Cardiovascular disease | MNDR-E-MI-36705 |
| MNDR | hsa-miR-30a-5p | Moyamoya disease | MNDR-E-MI-36706 |
| MNDR | hsa-miR-30a-5p | Brain cancer | MNDR-E-MI-36707 |
| MNDR | hsa-miR-30a-5p | Uterine fibroid | MNDR-E-MI-36708 |
| MNDR | hsa-miR-30a-5p | Lung cancer | MNDR-E-MI-36709 |
| MNDR | hsa-miR-30a-5p | Down syndrome | MNDR-E-MI-36710 |
| MNDR | hsa-miR-30a-5p | Parkinson disease | MNDR-E-MI-36711 |
| MNDR | hsa-miR-30a-5p | Colon carcinoma | MNDR-E-MI-36712 |
| MNDR | hsa-miR-30a-5p | Basal-like breast cancer | MNDR-E-MI-36713 |
| MNDR | hsa-miR-30a-5p | Squamous cell carcinoma | MNDR-E-MI-36714 |
| MNDR | hsa-miR-30a-5p | Thyroid cancer | MNDR-E-MI-36715 |
| MNDR | hsa-miR-30a-5p | Pituitary neoplasms | MNDR-E-MI-36716 |
| MNDR | hsa-miR-30a-5p | Pancreatic cancer | MNDR-E-MI-36717 |
| MNDR | hsa-miR-30a-5p | Melanoma | MNDR-E-MI-36718 |
| MNDR | hsa-miR-30a-5p | Rectum adenocarcinoma | MNDR-E-MI-36719 |
| MNDR | hsa-miR-30a-5p | Nephroblastoma | MNDR-E-MI-36720 |
| MNDR | hsa-miR-30a-5p | Colon cancer | MNDR-E-MI-36721 |
| MNDR | hsa-miR-30a-5p | Ischemic attack transient | MNDR-E-MI-36722 |
| MNDR | hsa-miR-30a-5p | Colon adenocarcinoma | MNDR-E-MI-36723 |
| MNDR | hsa-miR-30a-5p | Multiple sclerosis | MNDR-E-MI-36724 |
| MNDR | hsa-miR-30a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-36725 |
| MNDR | hsa-miR-30a-5p | Familial ovarian cancer | MNDR-E-MI-36726 |
| MNDR | hsa-miR-30a-5p | Acromegaly | MNDR-E-MI-36727 |
| MNDR | hsa-miR-30a-5p | Prostate adenocarcinoma | MNDR-E-MI-36728 |
| MNDR | hsa-miR-30a-5p | Carcinoma ductal breast | MNDR-E-MI-36729 |
| MNDR | hsa-miR-30a-5p | Balkan nephropathy | MNDR-E-MI-36730 |
| MNDR | hsa-miR-30a-5p | Glioblastoma | MNDR-E-MI-36731 |
| MNDR | hsa-miR-30a-5p | Glioma | MNDR-E-MI-36732 |
| MNDR | hsa-miR-30a-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-36733 |
| MNDR | hsa-miR-30a-5p | Temporal lobe epilepsy | MNDR-E-MI-36734 |
| MNDR | hsa-miR-30a-5p | Osteosarcoma | MNDR-E-MI-36735 |
| MNDR | hsa-miR-30a-5p | Liposarcoma | MNDR-E-MI-36736 |
| MNDR | hsa-miR-30a-5p | Carotid artery disease | MNDR-E-MI-36737 |
| MNDR | hsa-miR-30a-5p | Inclusion body myositis | MNDR-E-MI-36738 |
| MNDR | hsa-miR-30a-5p | Meningioma | MNDR-E-MI-36739 |
| MNDR | hsa-miR-30a-5p | Liver cancer | MNDR-E-MI-36740 |
| MNDR | hsa-miR-30a-5p | Uterine cancer | MNDR-E-MI-36741 |
| MNDR | hsa-miR-30a-5p | Cervical adenocarcinoma | MNDR-E-MI-36742 |
| MNDR | hsa-miR-30a-5p | Gastric adenocarcinoma | MNDR-E-MI-36743 |
| MNDR | hsa-miR-30a-5p | Pituitary adenoma | MNDR-E-MI-36744 |
| MNDR | hsa-miR-30a-5p | Lung squamous cell carcinoma | MNDR-E-MI-36745 |
| MNDR | hsa-miR-30a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-36746 |
| MNDR | hsa-miR-30a-5p | Lung adenocarcinoma | MNDR-E-MI-36747 |
| MNDR | hsa-miR-30a-5p | Adrenocortical cancer | MNDR-E-MI-36748 |
| MNDR | hsa-miR-30a-5p | Thyroid carcinoma | MNDR-E-MI-36749 |
| MNDR | hsa-miR-30a-5p | Bladder urothelial carcinoma | MNDR-E-MI-36750 |
| MNDR | hsa-miR-30a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-36751 |
| MNDR | hsa-miR-30a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-36752 |
| MNDR | hsa-miR-30a-5p | Carcinoma renal cell | MNDR-E-MI-36753 |
| MNDR | hsa-miR-30a-5p | Papillary renal cell carcinoma | MNDR-E-MI-36754 |
| MNDR | hsa-miR-30a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-36755 |
| MNDR | hsa-miR-30a-5p | Large cell carcinoma | MNDR-E-MI-36756 |
| MNDR | hsa-miR-30a-5p | Biliary tract cancer | MNDR-E-MI-36757 |
| MNDR | hsa-miR-30a-5p | Cholangiocarcinoma | MNDR-E-MI-36758 |
| MNDR | hsa-miR-30a-5p | Esophageal cancer | MNDR-E-MI-36759 |
| MNDR | hsa-miR-30a-5p | Prolactinoma | MNDR-E-MI-36760 |
| MNDR | hsa-miR-30a-5p | Lung small cell carcinoma | MNDR-E-MI-36761 |
| MNDR | hsa-miR-30a-5p | Schizophrenia | MNDR-E-MI-36762 |
| MNDR | hsa-miR-30a-5p | Variant creutzfeldt-jakob disease | MNDR-E-MI-36763 |
| MNDR | hsa-miR-30a-5p | Synovial sarcoma | MNDR-E-MI-36764 |
| MNDR | hsa-miR-30a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-36765 |
| MNDR | hsa-miR-30a-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-36766 |
| MNDR | hsa-miR-30a-5p | Breast invasive carcinoma | MNDR-E-MI-36767 |
| MNDR | hsa-miR-30a-5p | Hepatocellular carcinoma | MNDR-E-MI-36768 |
| MNDR | hsa-miR-30a-5p | Familiar ovarian carcinoma | MNDR-E-MI-36769 |
| MNDR | hsa-miR-30a-5p | B-cell lymphoma | MNDR-E-MI-36770 |
| MNDR | hsa-miR-30a-5p | Rheumatoid arthritis | MNDR-E-MI-36771 |
| MNDR | hsa-miR-30a-5p | T-cell leukemia | MNDR-E-MI-36772 |
| MNDR | hsa-miR-30a-5p | Abdominal aortic aneurysm | MNDR-E-MI-36773 |
| MNDR | hsa-miR-30a-5p | Osteoarthritis | MNDR-E-MI-36774 |
| MNDR | hsa-miR-30a-5p | Chronic myelogenous leukemia | MNDR-E-MI-36775 |
| MNDR | hsa-miR-30a-5p | Hodgkin lymphoma | MNDR-E-MI-36776 |
| MNDR | hsa-miR-30a-5p | Burkitt lymphoma | MNDR-E-MI-36777 |
| MNDR | hsa-miR-30a-5p | Tonsil cancer | MNDR-E-MI-36778 |
| MNDR | hsa-miR-30a-5p | Neuromyelitis optica | MNDR-E-MI-36779 |
| MNDR | hsa-miR-30a-5p | Colorectal cancer | MNDR-E-MI-36780 |
| MNDR | hsa-miR-30a-5p | Nasopharynx carcinoma | MNDR-E-MI-36781 |
| MNDR | hsa-miR-30a-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-36782 |
| MNDR | hsa-miR-30a-5p | Cardiomegaly | MNDR-E-MI-36783 |
| MNDR | hsa-miR-30a-5p | Nasopharyngeal cancer | MNDR-E-MI-36784 |
| MNDR | hsa-miR-30a-5p | Prostatic neoplasms | MNDR-E-MI-36785 |
| MNDR | hsa-miR-30a-5p | Pseudorabies | MNDR-E-MI-36786 |
| MNDR | hsa-miR-30a-5p | Sleep deprivation | MNDR-E-MI-36787 |
| MNDR | hsa-miR-30a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-36788 |
| MNDR | hsa-miR-30a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-36789 |
| MNDR | hsa-miR-30a-5p | Venous thromboembolism | MNDR-E-MI-36790 |
| MNDR | hsa-miR-30a-5p | Stroke lacunar | MNDR-E-MI-36791 |
| MNDR | hsa-miR-30a-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-36792 |
| MNDR | hsa-miR-30a-5p | Breast cancer her3+ negative | MNDR-E-MI-36793 |
| MNDR | hsa-miR-30a-5p | Duke A | MNDR-E-MI-36794 |
| MNDR | hsa-miR-30a-5p | Glomerular disease | MNDR-E-MI-36795 |
| MNDR | hsa-miR-30a-5p | Low grade dysplastic nodule | MNDR-E-MI-36796 |
| MNDR | hsa-miR-30a-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-36797 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABL1 | Homo sapiens | RR00026978 |
TOP